NASDAQ:CMPS 4 November 2025 - 22 June 2026

For live price, interactive charts, financials and the latest market data, visit Google Finance.

Definium Therapeutics (DFTX) jumps in premarket on Phase 3 depression trial

Definium Therapeutics Inc. surged in pre-market trading after the company said its LSD-based DT120 tablet hit the main target in a late-stage depression trial. The New York biotech traded at $40.19 on Public.com at 9:00 a.m. ET, up 64.2% from Friday’s close of $24.48. Nasdaq’s session hadn’t started yet, with the open set for 9:30 a.m. ET.

22 June 2026

NASDAQ:CMPS·NASDAQ:DFTX·Stock Market

Compass Pathways Rallies Pre-Market on FDA Trade Speculation

Compass Pathways plc jumped in U.S. premarket action Monday as the stock built on last week’s gains. Investors are reacting to signs of a quicker path for COMP360, the company’s psilocybin drug candidate for depression. The Nasdaq shares traded at $12.39 at 6:03 a.m. EDT, up 19.5% from Friday’s close at $10.37. Regular trading on Nasdaq begins at 9:30 a.m. Eastern.

18 May 2026

NASDAQ:CMPS·Stock Market

COMPASS Pathways (CMPS) Psychedelic Breakthrough Stock – Latest News, Analysis & 2025 Outlook

Below is a full breakdown of COMPASS Pathways’ recent performance, news, expert commentary, industry positioning, and an analysis of the stock’s fundamentals, technicals, and future scenarios.

4 November 2025

Biotechnology·NASDAQ:CMPS

Go toTop